Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218146 · ClinicalTrials.gov registry record · Phase 3
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
A Phase 3 study of Small-cell Lung Cancer, sponsored by Zai Lab (Shanghai) Co..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
- 14
- Study locations
NCT07218146 is a Phase 3 study of Small-cell Lung Cancer that is actively recruiting participants, run by Zai Lab (Shanghai) Co.. The registered enrollment target is 480 participants, above the 226-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (112% higher). The trial reports 14 study locations across 9 states.
The verdict
NCT07218146, a Phase 3 study of Small-cell Lung Cancer, is actively recruiting participants, sponsored by Zai Lab (Shanghai) Co..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Conditions Studied
Interventions
- DRUG ZL-1310
- DRUG Investigator's Choice of Therapy
Study Locations (14)
Florida
- Zai Lab Site 02045 - Clermont
- Zai Lab Site 02031 - Orange City
- Zai Lab Site 02020 - Rockledge
- Zai Lab Site 02026 - Sarasota
Illinois
- Zai Lab Site 02021 - Peoria
- Zai Lab Site 02049 - Peoria
Pennsylvania
- Zai Lab Site 02035 - Broomall
- Zai Lab Site 02019 - Media
Kentucky
- Zai Lab Site 02041 - Louisville
Maryland
- Zai Lab Site 02003 - Bethesda
Missouri
- Zai Lab Site 02023 - Columbia
Tennessee
- Zai Lab Site 02036 - Nashville
Texas
- Zai Lab Site 02025 - Odessa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2025-11-30 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218146
The ClinicalTrials.gov registry entry for NCT07218146 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 226-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (112% higher). The listed sponsor is Zai Lab (Shanghai) Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which ZL-1310 is the first listed.
NCT07218146 reports 14 study locations spanning 9 distinct geographic areas - top geographies include Florida, Illinois, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07218146 about?
NCT07218146 is a clinical study titled "A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)". The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
What is the current status of trial NCT07218146?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2025-11-30. Estimated completion is 2028-11-30.
What conditions does trial NCT07218146 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT07218146?
The interventions under investigation include: ZL-1310 (DRUG), Investigator's Choice of Therapy (DRUG).
Who is sponsoring clinical trial NCT07218146?
This trial is sponsored by Zai Lab (Shanghai) Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218146 being conducted?
This trial has 14 study locations across Florida, Illinois, Kentucky, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
RECRUITING · Phase 3
-
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
ACTIVE NOT RECRUITING · Phase 3
-
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.